Áttétes emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

33+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, Egyesült Államok· until 2028. okt.

• NIH NIDA · UG3

  Development of a Novel Treatment for Benzodiazepine Addiction

  University of Mississippi Med Ctr· Jackson, Egyesült Államok· 1 753 289 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, Egyesült Államok· 40 326 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, Egyesült Államok· 564 078 USD awarded in fiscal year 2026· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Re-wiring tumor immune-evasive plasticity with mRNA therapy (PLASTWIRE)

  Fundacio Institut Hospital del Mar D Investigacions Mediques· Barcelona, Spanyolország· EU contribution 2 533 207 EUR· until 2031. nov.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multispecific theranostic nano-engager platform (Nano-BITE)

  Institut Gustave Roussy· Villejuif, Franciaország· EU contribution 150 000 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

10 of 2354 running projects, newest first. Listed amounts together: 1,3 Mrd USD + 289,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Frissítve: 2024. máj. 2.

  “No subjects enrolled in the study”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Forrás

• Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

  NCT04039230· Massachusetts General Hospital· Forrás

• Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

  NCT03990896· Massachusetts General Hospital· Forrás

• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· AstraZeneca· Forrás

• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· GBG Forschungs GmbH· Forrás

• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

  NCT00516724· AstraZeneca· Forrás

• A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· AbbVie· Forrás

• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET.

  J Nucl Med, 2026. szept.

• Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification.

  Cancer Imaging, 2026. aug.

• [18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

  Breast, 2026. júl.

• RECIST 1.1 and PERCIST for response assessment in metastatic breast cancer: feasibility and agreement in a real‑world retrospective cohort study.

  Eur J Radiol, 2026. júl.

• Diagnostic Accuracy of PET Imaging for Lymph Node Detection in Breast cancer patients undergoing Upfront Surgery: A Single-Institution Analysis of Breast Cancer Patients.

  F1000Res, 2026. jún.

• 18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial.

  JAMA Oncol, 2026. jún.

• Cost-Effectiveness of Integrated Fluorodeoxyglucose PET/MR With Low-Dose Chest CT for Initial Staging of Locally Advanced Breast Cancer.

  J Am Coll Radiol, 2026. máj.

  Onofrio Antonio Catalano

• Performance of [68Ga]Ga-FAPI PET in Breast, Ovarian, and Cervical Cancers: A Systematic Review and Meta-Analysis.

  Asian Pac J Cancer Prev, 2026. ápr.

• Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.

  Breast Cancer Res Treat, 2026. márc.

• The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.

  Nucl Med Commun, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.